EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current status and future perspectives of multi‐modal bacteria‐based cancer therapies

Shuai Fan iD, Siyu Zhu, Wenyu Wang, Yuetong Liu, Yutong Zhou, Hao Li, Bofeng Liu, Qin Xia, Lili Huang, Lei Dong iD

Clinical and Translational Medicine · 2025-10 · 15 (10)

DOI: 10.1002/ctm2.70485 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 21.10.2025. Verfasst von Shuai Fan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Technology Research Institute, State Key Laboratory of Molecular Medicine and Biological Diagnosis and Treatment (Ministry of Industry and I…. Hauptthemen laut MEDLINE: Neoplasms, Drug Delivery Systems, Bacteria. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Natural Science Foundation, National Natural Science Foundation of China, Shandong Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Targeted drug delivery systems have garnered increasing research interest in cancer threapy. Bacteria have emerged as a promising vehicle due to their innate ability to the tumour microenvironment (TME) and their intrinsic immune‐stimulating properties. This review explores the application of bacteria in oncology, emphasizing the tumour‐targeting behaviour of specific strains, their immunomodulatory functions, and their potential as delivery platforms for the controlled release of therapeutic agents. Main text This review synthesizes recent advances in bacteria‐mediated cancer therapy, focusing on the mechanisms underlying bacterial targeting of hypoxic and immunosuppressive regions within the tumor microenvironment (TME). We discuss how genetic modification has been employed to design recombinant bacterial strains with enhanced tumor specificity and amplified therapeutic effects. Furthermore, the integration of bacteria with nanotechnology has facilitated the development of hybrid systems capable of targeted drug delivery and triggered‐release mechanisms. The combination of bacterial therapy with other treatment modalities—such as photodynamic (PDT) and sonodynamic therapies (SDT)—is also examined, emphasizing their synergistic potential in overcoming tumor heterogeneity and enhancing anti‐tumor immunity. Finally, we survey the current clinical progress of bacteria‐based therapeutics and offer perspectives on the future role of artificial intelligence (AI) in improving the design and application of these living medicines.

Conclusions

Bacteria‐based delivery systems represent a multifunctional and innovative strategy in the evolution of targeted cancer therapies. Through genetic modification and nanobiotechnology approaches, bacteria can be customized to mediate multi‐effect synergistic treatments for cancer, enhancing the precision, safety, and efficacy of cancer therapies. With the ongoing integration of advanced technologies, including AI, there is great potential to overcome existing limitations and accelerate the clinical translation of bacterial anticancer therapies. This interdisciplinary effort is poised to open new avenues for next‐generation cancer treatments and lay the foundation for future directions in cancer research and therapeutic practice. Key points Bacteria exhibit inherent tumour‐targeting capabilities, particularly thriving in hypoxic tumour microenvironments (TMEs) and activating potent anti‐tumour immune responses through pathogen‐associated molecular patterns (PAMPs) and immunomodulation. Genetic engineering and nanobiotechnology enable advanced bacterial therapies, allowing for reduced toxicity, controlled proliferation, targeted drug delivery and the expression of therapeutic payloads (e.g., cytokines, enzymes, tumour antigens) within tumours. Bacteria serve as versatile platforms for multi‐modal synergistic therapy, effectively combining with immunotherapy, photodynamic therapy (PDT), thermodynamic therapy (TDT), photothermal therapy (PTT) and sonodynamic therapy (SDT) to significantly enhance tumour eradication. Artificial intelligence (AI) is poised to revolutionise bacterial cancer therapy, offering powerful tools for optimising synthetic biology designs (e.g., promoters, gene circuits), nanocarrier engineering and predicting bacterial–host interactions for more effective and safer treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsDrug Delivery SystemsBacteriaHumansTumor Microenvironment

Stichwörter der Autor:innen

TMEbacteriacancergenetic modificationnanotechnologysynergistic therapy

Autor:innen und Institutionen

  • Advanced Technology Research Institute, State Key Laboratory of Molecular Medicine and Biological Diagnosis and Treatment (Ministry of Industry and Information Technology), School of Life Science, Beijing Institute of T…
  • School of Medical Technology, Beijing Institute of Technology, Beijing, China.
  • China Talent Group, Beijing, China.

ORCID-Profile: Shuai Fan, Lei Dong

Förderung

  • Beijing Municipal Natural Science Foundation
  • National Natural Science Foundation of China
  • Shandong Provincial Natural Science Foundation
  • Hebei Natural Science Foundation
  • Fundamental Research Funds for the Central Universities
  • Natural Science Foundation of Beijing Municipality
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Fan, S., Zhu, S., Wang, W., Liu, Y., Zhou, Y., Li, H., Liu, B., Xia, Q., Huang, L., & Dong, L. (2025). Current status and future perspectives of multi‐modal bacteria‐based cancer therapies. Clinical and Translational Medicine, 15(10). https://doi.org/10.1002/ctm2.70485

Vancouver

Fan S, Zhu S, Wang W, Liu Y, Zhou Y, Li H, et al. Current status and future perspectives of multi‐modal bacteria‐based cancer therapies. Clinical and Translational Medicine. 2025;15(10). doi:10.1002/ctm2.70485

BibTeX
@article{Fan2025,
  author = {Fan, Shuai and Zhu, Siyu and Wang, Wenyu and Liu, Yuetong and Zhou, Yutong and Li, Hao and Liu, Bofeng and Xia, Qin and Huang, Lili and Dong, Lei},
  title = {Current status and future perspectives of multi‐modal bacteria‐based cancer therapies},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  volume = {15},
  number = {10},
  doi = {10.1002/ctm2.70485}
}
Kostenlos starten →